Biophytis S.A. (ALBPS) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.472x

Based on the latest financial reports, Biophytis S.A. (ALBPS) has a cash flow conversion efficiency ratio of 0.472x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.69 Million ≈ $-4.32 Million USD) by net assets (€-7.82 Million ≈ $-9.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALBPS market cap overview for the company's overall valuation and market capitalisation.

Biophytis S.A. - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Biophytis S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Biophytis S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biophytis S.A. ranked by their cash flow conversion efficiency. See Biophytis S.A. (ALBPS) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
Smooth Rock Ventures Corp
V:SMRV
-0.028x
Agrogalaxy Participacoes SA
SA:AGXY3
-0.339x
Sodas Sodyum Sanayi AS
IS:SODSN
0.362x
4GLOBAL LS-01
F:HS9
N/A
Ganga Forging Limited
NSE:GANGAFORGE
0.016x
Yari Minerals Ltd
AU:YAR
-1.583x
Vp plc
LSE:VP
0.245x
Begbies Traynor Group PLC
LSE:BEG
-0.014x

Annual Cash Flow Conversion Efficiency for Biophytis S.A. (2013–2024)

The table below shows the annual cash flow conversion efficiency of Biophytis S.A. from 2013 to 2024. View Biophytis S.A. stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €-9.70 Million
≈ $-11.34 Million
€-8.64 Million
≈ $-10.10 Million
0.891x -73.09%
2023-12-31 €-3.89 Million
≈ $-4.55 Million
€-12.87 Million
≈ $-15.05 Million
3.310x -66.69%
2022-12-31 €-1.91 Million
≈ $-2.23 Million
€-18.99 Million
≈ $-22.20 Million
9.936x +338.23%
2021-12-31 €5.71 Million
≈ $6.67 Million
€-23.80 Million
≈ $-27.82 Million
-4.171x -188.88%
2020-12-31 €6.83 Million
≈ $7.99 Million
€-9.86 Million
≈ $-11.53 Million
-1.444x -171.15%
2019-12-31 €-7.53 Million
≈ $-8.80 Million
€-15.27 Million
≈ $-17.86 Million
2.029x +217.92%
2018-12-31 €7.01 Million
≈ $8.19 Million
€-12.06 Million
≈ $-14.10 Million
-1.721x -317.79%
2017-12-31 €21.19 Million
≈ $24.77 Million
€-8.73 Million
≈ $-10.20 Million
-0.412x +71.94%
2016-12-31 €4.52 Million
≈ $5.28 Million
€-6.63 Million
≈ $-7.75 Million
-1.468x -433.55%
2015-12-31 €11.67 Million
≈ $13.64 Million
€-3.21 Million
≈ $-3.75 Million
-0.275x -147.13%
2014-12-31 €-1.13 Million
≈ $-1.32 Million
€-658.89K
≈ $-770.31K
0.584x -70.26%
2013-12-31 €-409.32K
≈ $-478.54K
€-803.29K
≈ $-939.14K
1.962x --

About Biophytis S.A.

PA:ALBPS France Biotechnology
Market Cap
$2.50 Million
€2.14 Million EUR
Market Cap Rank
#29891 Global
#546 in France
Share Price
€0.05
Change (1 day)
+1.60%
52-Week Range
€0.01 - €0.17
All Time High
€4896.00
About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more